Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04650542
Registration number
NCT04650542
Ethics application status
Date submitted
13/11/2020
Date registered
2/12/2020
Date last updated
15/07/2022
Titles & IDs
Public title
Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects
Query!
Scientific title
Open-Label, Two-Period Phase 1 Study in Healthy Subjects to Evaluate the Potential Effect of Multiple Doses of Paroxetine on the Pharmacokinetics and Safety of HBI-3000
Query!
Secondary ID [1]
0
0
HBI-3000-401
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Drug-drug Interaction
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - HBI-3000
Treatment: Drugs - Paroxetine
Experimental: HBI-3000 alone (Period 1) followed by HBI-3000 with Paroxetine (Period 2) - HBI-3000: 350 mg, 50 mL intravenous infusion (IV) over 30 minutes on Day 1 of Period 1 and approximately 15 days later on Day 1 of Period 2
Paroxetine: 20 mg dose twice a day on Days 1 and 2 of Period 2, and once a day on Days 3 through 7 inclusive of Period 2
Treatment: Drugs: HBI-3000
small molecule, multi-ion channel blocker
Treatment: Drugs: Paroxetine
serotonin uptake inhibitor, CYP2D6 inhibitor
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Plasma pharmacokinetics (PK): Maximum observed plasma concentration (Cmax)
Query!
Assessment method [1]
0
0
To determine the plasma Cmax of a single dose of HBI 3000 administered intravenously (IV), in the absence and the presence of CYP2D6 inhibition, achieved with multiple oral doses of paroxetine, a strong CYP2D6 inhibitor, in healthy male and female subjects. Blood samples will be taken from 0 through 72 hours after the start of HBI-3000 infusion.
Query!
Timepoint [1]
0
0
72 hours
Query!
Primary outcome [2]
0
0
Plasma pharmacokinetics (PK): Area Under the Curve (AUC) from time 0 to last measurable concentration (AUC0 - tau)
Query!
Assessment method [2]
0
0
To determine the plasma AUC of a single dose of HBI 3000 administered intravenously (IV), in the absence and the presence of CYP2D6 inhibition, achieved with multiple oral doses of paroxetine, a strong CYP2D6 inhibitor, in healthy male and female subjects. Blood samples will be taken from 0 through 72 hours after the start of HBI-3000 infusion.
Query!
Timepoint [2]
0
0
72 hours
Query!
Primary outcome [3]
0
0
Plasma pharmacokinetics (PK): Area Under the Curve (AUC) from time 0 to infinity (AUC0 - infinity), if data permits
Query!
Assessment method [3]
0
0
To determine the plasma AUC of a single dose of HBI 3000 administered intravenously (IV), in the absence and the presence of CYP2D6 inhibition, achieved with multiple oral doses of paroxetine, a strong CYP2D6 inhibitor, in healthy male and female subjects. Blood samples will be taken from 0 through 72 hours after the start of HBI-3000 infusion.
Query!
Timepoint [3]
0
0
72 hours
Query!
Secondary outcome [1]
0
0
Treatment-Emergent Adverse Events (TEAEs), including serious TEAEs
Query!
Assessment method [1]
0
0
To evaluate the safety and tolerability of HBI-3000 in the absence and the presence of paroxetine, as measured by Treatment-Emergent Adverse Events (TEAEs), including serious TEAEs. TEAE is defined as follows: An AE that emerges during treatment, having been absent at pretreatment (Baseline), an AE that re emerges during treatment, having been present at pretreatment (Baseline) but stopped before treatment, or an AE that worsens in severity during treatment relative to the pretreatment state, when the AE is ongoing. TEAEs will be recorded for approximately 25 days commencing with the start of HBI-3000 infusion.
Query!
Timepoint [1]
0
0
25 days
Query!
Secondary outcome [2]
0
0
Routine hematology and coagulation
Query!
Assessment method [2]
0
0
To evaluate the safety and tolerability of HBI-3000 in the absence and the presence of paroxetine, as measured by routine hematology and coagulation tests, at Screening and periodically during the study, including: Hematocrit (Packed cell volume); Hemoglobin; Lymphocytes; Mean cell hemoglobin Mean cell hemoglobin concentration; Mean cell volume; Basophils; Eosinophils; Monocytes; Neutrophils; Platelet count; Red blood cell count; White blood cell count; Coagulation Tests; Prothrombin time; International normalised ratio; Partial thromboplastin time
Query!
Timepoint [2]
0
0
25 days
Query!
Secondary outcome [3]
0
0
Routine serum chemistry
Query!
Assessment method [3]
0
0
To evaluate the safety and tolerability of HBI-3000 in the absence and the presence of paroxetine, as measured by routine serum clinical chemistry tests, at Screening and periodically during the study, including: Alanine aminotransferase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Bicarbonate; Bilirubin (total); Bilirubin (direct); Calcium; Chloride; Cholesterol; Creatine kinase; Creatinine, estimated clearance; Gamma glutamyl transferase; Triglycerides; Globulin; A/G ratio; Glucose; Magnesium; Potassium; Phosphate (inorganic); Protein (total); Sodium; Urea; Uric acid
Query!
Timepoint [3]
0
0
25 days
Query!
Secondary outcome [4]
0
0
Vitals signs
Query!
Assessment method [4]
0
0
To evaluate the safety and tolerability of HBI-3000 in the absence and the presence of paroxetine, as measured by vitals signs including heart rate and blood pressure using an automated blood pressure device, at Screening and periodically during the study.
Query!
Timepoint [4]
0
0
25 days
Query!
Secondary outcome [5]
0
0
12-lead ECG
Query!
Assessment method [5]
0
0
To evaluate the safety and tolerability of HBI-3000 in the absence and the presence of paroxetine, as measured by 12-lead ECG. Twelve-lead ECGs will be measured at Screening and periodically during the study using standardized equipment provided by the core ECG laboratory and reviewed locally by the Investigator. QTc interval will be calculated from Fridericia's formula.
Query!
Timepoint [5]
0
0
25 days
Query!
Secondary outcome [6]
0
0
Continuous telemetry
Query!
Assessment method [6]
0
0
To evaluate the safety and tolerability of HBI-3000 in the absence and the presence of paroxetine, as measured by monitoring via a continuous cardiac telemetry monitoring system for 8 hours commencing with the start of HBI-3000 infusion
Query!
Timepoint [6]
0
0
8 hours beginning at the start of infusion
Query!
Secondary outcome [7]
0
0
Infusion site (local) reactions
Query!
Assessment method [7]
0
0
To evaluate the safety and tolerability of HBI-3000 in the absence and the presence of paroxetine, as measured by observing infusion site (local) reactions for the duration of the study (approximately 25 days) commencing with the start of HBI-3000 infusion
Query!
Timepoint [7]
0
0
25 days
Query!
Secondary outcome [8]
0
0
Physical examination findings
Query!
Assessment method [8]
0
0
To evaluate the safety and tolerability of HBI-3000 in the absence and the presence of paroxetine, as measured by examination of body systems and symptom directed examination as indicated, at Screening and during the study (approximately 25 days)
Query!
Timepoint [8]
0
0
25 days
Query!
Secondary outcome [9]
0
0
Left ventricular ejection fraction (LVEF), Exploratory
Query!
Assessment method [9]
0
0
To evaluate the safety and tolerability of HBI-3000 in the absence of paroxetine, as measured by 2D transthoracic echocardiogram to measure changes in cardiac contractility, determined at baseline and at 30 minutes and 2 hours after the start of infusion
Query!
Timepoint [9]
0
0
At baseline and 2 hours beginning at the start of infusion
Query!
Eligibility
Key inclusion criteria
Healthy adult males and females
- 18 - 50 years of age
- BMI 18 - 32 kg/m2
- Subject has no clinically significant abnormality on electrocardiogram (ECG)
- Subject has been a nonsmoker and/or has not used nicotine or nicotine-containing
products for at least 4 months
- Subject is willing to comply with the study restrictions, including contraception
requirements
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
50
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- Evidence of a clinically significant disease or abnormalities, including an active,
current infection or clinically significant infection within 8 weeks prior to the
first dose
- Severe allergic reaction, angioedema, or anaphylaxis to drugs, or food or latex
allergies
- Subject has an estimated creatinine clearance of = 70 mL
- Subject has evidence of a clinically significant deviation from normal in the physical
examination, vital signs, or clinical laboratory determinations
- Subject has significant ECG abnormality, history or presence of cardiac arrhythmia or
conduction abnormalities, or bradycardia (< 45 bpm)
- Subject has a history of vasovagal syncope, or symptomatic orthostatic hypotension
- Subject has as a history of or current alcohol abuse and/or other drug addiction
- Subject has received an investigational drug (including investigational vaccines)
within 5 half-lives of such drug prior to Study Day 1
- Subject has received CYP2D inhibitors (e.g., fluoxetine, sertraline, duloxetine,
bupropion, chloroquine, cimetidine, diphenhydramine) less than 3 weeks prior to
administration of the initial dose of study drug
- Subject has suicidal thinking and behavior (suicidality) or other significant
psychiatric disorders based on self-disclosure during interview (Screening visit)
- Subject has a history of acute narrow-angle glaucoma
- Subject has as any condition that would make him or her, in the opinion of the
Investigator or Sponsor, unsuitable for the study
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
21/02/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
13/08/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
39
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Nucleus Network Pty Ltd. - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
- Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Wisconsin
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
HUYABIO International, LLC.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female
Subjects
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04650542
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Jason Lickliter, MD
Query!
Address
0
0
Nucleus Network
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04650542
Download to PDF